Objectives: Lidocaine is the most commonly used local anaesthetic in clinical and can inhibit proliferation, suppress invasion and migration and induce apoptosis in human lung adenocarcinoma (LAD) cells. However, its specific downstream molecular mechanism is unclear. 
| INTRODUCTION
Retrospective studies have found that cancer patients can benefit from local anaesthesia to reduce cancer recurrence and improve survival rate [1] [2] [3] . Lidocaine is one of the most commonly used local anaesthetic in clinical and can inhibit proliferation, suppress invasion and migration, and induce apoptosis in many cancers [4] [5] [6] . In human thyroid cancer cells, lidocaine induces apoptosis by regulating the mitogenactivated protein kinase pathway. 5 Lidocaine also inhibited the growth of HepG2 cells in a dose-and time-dependent manner with the increase of Bax protein and activated caspase-3 and a corresponding decrease in Bcl-2 protein. 6 Lidocaine could block the TNFα-induced increase of invasion in lung cancer cells. 7, 8 However, whether lidocaine regulates the lung cancer cells viability remains largely unknown. The downstream molecular mechanism is also unclear.
Lung adenocarcinoma (LAD) is one of the most common malignant cancers and leads to most of deaths. 9 LAD has become the most common subtype of lung cancers. 10 Although there is rapid development of treatment methods including of surgical resection, chemotherapy and radiotherapy in recent decades, the survival rate of patients still have not been improved significantly. 11 Rapid proliferation of lung cancer cells results of the malignant enlargement with compression on organs and subsequent metastasis and invasion. Proliferation is regulated by an array of genes. Recent studies showed that Golgi-related genes significantly regulate the tumorigenesis and development.
12,13
Golgi phosphor protein 2 (GOLPH2) has been reported to be correlated with many diseases including of prostate cancer, and renal cell cancer. [14] [15] [16] Overexpression of GOLPH3 correlates with poor response to new adjuvant therapy in locally advanced rectal cancer.
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Overexpression of GOLPH3 also is associated with poor survival and regulates the metastasis through MMP-2 and MMP-9 in non-smallcell lung cancer. 18 Golgi transport 1A (GOLT1A) modulates tamoxifen sensitivity in breast cancer cells. 19 However, less report showed the function of GOLT1A in lung cancer cells, and the related molecular mechanism remains largely unknown.
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In this study, we found that GOLT1A expression was significantly elevated in LAD patients tissue samples analysed from TCGA database. High level of GOLT1A was related to the poor prognosis and adverse pathological T stage. Downregulation of GOLT1A repressed the proliferation and induced the cell cycle arrest of lung cancer cells.
Lidocaine repressed the cell proliferation by downregulating the GOLT1A. In this study, we indicated the function of GOLT1A on LAD cells proliferation. Lidocaine repressed the cell proliferation by downregulating the GOLT1A. Our studies may lay the foundation for therapeutic treatment of lidocaine for lung cancer.
| MATERIALS AND METHODS

| Cell culture and lidocaine treatment
Human lung cancer cell lines A549, were purchased from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium (GIBCO, New York, NY, USA) supplemented with 10% foetal bovine serum (GIBCO), 100 mg/mL of streptomycin sulphate (Invitrogen, Life Technologies, Carlsbad, CA, USA), and 100 U/mL of penicillin sodium (Invitrogen) at 37°C, 5% CO 2 atmosphere in air. The concentrations of lidocaine were based on previous study. 
| mRNAs Quantitative PCR (qPCR)
Total RNA was extracted by RNAiso plus (Takara, Kusatsu, Japan) and used to synthesize cDNA by reverse transcription PCR kit 
| GOLT1A siRNA
The sequence of siRNA was referenced from the previous study.
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The sequences are as followed:
siRNA1GOLT1A (5′-GAUUCUUCAGCCUCUUUAAGG-3′ and 5′-U UAAAGAGGCUGAAGAAUCCG-3′) and siGOLT1A-2 (5′-GAAACCUA CGGAUUCUUCA-3′ and 5′-UGAAGAAUCCGUAGGUUUCCA-3′).
| Overexpression of GOLT1A
cDNA was synthesized by reverse transcription PCR kit (Takara) from total RNA isolated from A549 cells. The GOLT1A CDS fragment was inserted into the Fugw vector. The PCR primers are as follows: forward: 5′-GGCGGATCCATGATCTCCATCACCGAATGGC-3′ (BamH1 restriction enzyme), reverse: 5′-GGCGAATTCTCAGACCATCGAGCT AGTGCCTT-3′ (EcoR1 restriction enzyme).
| Western blot
Protein was lysed from cells by SDS lysis buffer (Beyotime Biotechnology, Nantong, China) and used for electrophoretic analysis. 
| Bromodeoxyuridine (BrdU) incorporation analysis
Cells were seeded in 96 wells (3×10 
| Proliferation assay
| Survival analysis
Whole genome mRNA expression data and clinical data of 501 LAD cancer samples were obtained from TCGA database (http://cancergenome.nih.gov/). For survival analysis, patients were separated into two groups according to median expression level of Golt1A.
| Clinic-pathologic parameters comparative analysis
Whole genome mRNA expression data and clinical data of 515 LAD samples were obtained from TCGA database (http://cancergenome.
nih.gov/). We used RSEM value for downstream analysis. We compared Golt1A's expression level in different pathologic T stage.
We drew box plot of Golt1A's expression for different pathologic stage T.
| Statistical analyses
In order to determine statistical significance, Student's t test or oneway ANOVA was used. Values were presented as the mean±SD, *P<.05,**P<.01, ***P<.001 respectively.
| RESULTS
| Lidocaine suppressed the proliferation of LAD cells
Lidocaine suppressed the proliferation of LAD cell lines A549 in a dosedependent manner detected by MTT assay ( Figure 1A ) and BrdU assay ( Figure 1B) , and lidocaine could also repress the H1299 cells proliferation ( Figure S1A ). Cyclin D1 was expressed, Cyclin E1 was downregulated, and Cdkn1a and Cdkn1b were upregulated in A549 cells after lidocaine treatment ( Figure 1C) . Additionally, the proportion of G1
phase cells was increased in the A549 cells after lidocaine treatment, while proportion of S and G2/M phase cells was decreased ( Figure 1D ).
Additionally, we used the flow cytometry assay (FACS) to detect the apoptosis and found lidocaine can induce the apoptosis of A549 cells ( Figure S1B ).
| Higher expression of GOLT1A is critically involved in the poor prognosis and higher grade malignancy
Lidocaine suppressed the expression of GOLT1A in A549 cells in a dose-dependent manner (Figure 2A) . We therefore analysed the data from the TCGA database of lung cancer patients' cancer and normal samples and found that GOLT1A was significantly upregulated in cancer samples compared with normal tissues ( Figure 2B ).
We then analysed the survival rate of the high-and low-GOLT1A expression level groups of LAD patient's samples and found that high level of GOLT1A groups was involved in the lower survival ratio ( Figure 2C ). The tumour, node, metastases (TNM) stage system is used to classify patients for participation in clinical treatment or trials. 20 We found that the expression level of GOLT1A was associated with the T stage, especially the T3 and T4 stage, which suggested that upregulation of GOLT1A was related with the increase of tumour ( Figure 2D ). ( Figure 3D ). We then detected that the G1 phase relative gene Cyclin D1, Cyclin E1 expression were downregulated. We also found that cell cycle inhibitors, Cdkn1a, Cdkn1b, were upregulated ( Figure 3E ).
In the contrary, overexpression of GOLT1A ( Figure 3F ) promoted the proliferation of A549 ( Figure 3G ,H) and H1299 cells ( Figure   S2B ). We also found that overexpression of GOLT1A significantly downregulated the proportion of G1 phase cells, and upregulated the S and G2/M phase cells of A549 cells ( Figure 3I ). We then detected that the overexpression of GOLT1A upregulated Cyclin D1 and Cyclin E1 and downregulated Cdkn1a and Cdkn1b ( Figure 3J ).
| GOLT1A mediates the function of lidocaine on repressing proliferation
We performed the rescue experiment to detect whether lidocaine represses the proliferation through GOLT1A. After overexpressing the GOLT1A in the A549 cells, we treated cells with lidocaine ( Figure 4A) and found that GOLT1A blocked the proliferation repression caused by lidocaine ( Figure 4B ,C). The GOLT1A restored the expression level of Cyclin D1, Cyclin E1, Cdkn1a and Cdkn1b influenced by lidocaine Figure 4D) . Additionally, overexpression of GOLT1A also restored the cell cycle arrest caused by lidocaine treatment ( Figure 4E ).
| DISCUSSION
As a major cause of global cancer-related deaths, lung cancer has greater annual burden than any other cancers, of which more than 85% of cases are currently classified as NSCLC. 21, 22 More than half of the NSCLC cases were adenocarcinoma. 23 Despite recent advances in diagnosis and treatment, the predicted 5-year survival rate is only 15.9% in the last few decades with only a minor improvement.
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A retrospective study of patients undergoing cancer surgery
showed that the use of regional anaesthesia reduced the risk of tumour metastasis and recurrence, but the mechanism remains unclear.
1-3
One of the most important advantages of regional anaesthetics is that they can reduce tumour cells viability, but do not in normal tissues.
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Lidocaine, the most commonly used local anaesthetic in the clinic, inhibits proliferation, invasion and migration and also induces apoptosis in different cancers. 5, 6, 26 Recent studies have found that lidocaine can reduce viability of human lung cancer cells, but its specific downstream molecular mechanism has been poorly studied. 7, 8 In our study, we proved that the lidocaine repressed the proliferation of LAD cells in a dose-dependent manner.
Many gene expression microarray and bioinformatics analysis
of the patients sample showed much new insight into the detection and treatment of cancer cells. Golgi-related genes were also reported to be the critical potential biomarkers of many kinds of cancers.
12,13
Golgi phosphoprotein-3 (GOLPH3) has been reported to be common in early-stage NSCC and be associated with tumour progression, increased tumour angiogenesis and poor survival. 27 Golgi protein-73 might be the potential biomarkers for diagnosis of hepatocellular carcinoma.
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In this study, we found that GOLT1A was upregulated in the LAD patients' samples, which showed that abnormal expression of GOLT1A was related to the tumorigenesis. Low expression of GOLT1A was 30 In this study, we found that knockdown of GOLT1A significantly inhibited the proliferation of LAD cell line. In the contrary, overexpression of GOLT1A promoted the proliferation. We also found that the cell cycle was influenced by GOLT1A. Cyclin D1 and Cyclin E1 are critical checkpoint proteins that regulate cells from G1 to S phase. 31, 32 The overexpression of Cyclin D1 and Cyclin E1 is associated with poor prognosis and can significantly reduce post-operative long-term survival. 33 Our study showed that the expression of Cyclin D1 and Cyclin E1 is downregulated, which prevents cells from moving from G1 to S phase, thereby inhibiting cell growth. Cell cycle inhibitors, Cdkn1a and Cdkn1b, were upregulated. These results showed the critical role of GOLT1A on regulating the LAD cell growth and suggested the downstream molecular signalling pathway related to the cell cycle regulation. GOLT1A also may be the novel therapeutic target for future lung cancer treatment.
Recent studies showed that oestrogen receptors play an important role in tumorigenesis. In lung cancer cells, oestrogen stimulates tumour progression and metastasis. 34 ZEB1 induces oestrogen receptor-α (ER-α) promoter hypermethylation and confers anti-oestrogen resistance in breast cancer. 35 Positive ERα was also associated with poor prognosis of Chinese gastric cancer patients. 36 Recent study
showed that GOLT1A was selected as one of the miR-378a-3p candidate target genes by in silico analysis and miR-378a-3p-dependent GOLT1A expression may be one mechanism underlying breast cancer endocrine resistance. 19 These studies suggested the critical roles of oestrogen receptor on regulating tumorigenesis. In this study, GOLT1A blocked the inhibition of lidocaine-induced proliferation.
GOLT1A restored the expression levels of Cyclin D1, Cyclin E1, Cdkn1a and Cdkn1b affected by lidocaine. In addition, GOLT1A also restored lidocaine-induced cell cycle arrest. These effects of GOLT1A may be achieved through the modulation of oestrogen receptor. Taken together, GOLT1A is a mediator of lidocaine for inhibiting the proliferation of lung cancer cells.
In summary, our results suggest that GOLT1A affects lung cancer cell proliferation by regulating cell cycle. Lidocaine may downregulate GOLT1A to inhibit the proliferation of lung cancer cells.
